Form 4: Tyra Biosciences COO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Tyra Biosciences' Chief Operating Officer, Daniel Bensen, sold a total of 125,589 shares of common stock in two transactions in November 2025 under a pre-arranged 10b5-1 trading plan.
Summary
- Daniel Bensen, Chief Operating Officer of Tyra Biosciences, Inc. (TYRA), reported sales of common stock.
- The sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Bensen on November 5, 2024.
- On November 18, 2025, Mr. Bensen disposed of 75,633 shares of common stock at a weighted average price of $16.0727 per share.
- Following the November 18, 2025 transaction, Mr. Bensen beneficially owned 220,937 shares of common stock directly.
- On November 19, 2025, an additional 49,956 shares of common stock were disposed of at a weighted average price of $16.3203 per share.
- After the November 19, 2025 transaction, Mr. Bensen's direct beneficial ownership of common stock was 170,981 shares.
- The actual sale prices for the November 18, 2025 transaction ranged from $16.00 to $16.24.
- The actual sale prices for the November 19, 2025 transaction ranged from $16.04 to $16.68.
Sentiment
Score: 6
Explanation: The filing reports a pre-scheduled insider sale under a 10b5-1 plan, which typically indicates a planned liquidity event rather than a reaction to new company-specific negative news. While insider selling can sometimes be viewed negatively by investors, the pre-arranged nature mitigates immediate concerns, placing the sentiment as neutral to slightly positive due to transparency.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This Form 4 filing is a standard disclosure of an insider stock transaction and does not provide information related to broader industry trends or competitive landscape. It reflects an individual officer's pre-planned stock sales rather than a strategic company move.
Stakeholder Impact
- Shareholders may interpret the insider sale as a signal, though the 10b5-1 plan suggests it's not based on new, undisclosed information. The transparency of the filing provides clarity on management's stock holdings.
Key Dates
| Date | Description |
|---|---|
| 11/05/2024 | Date Reporting Person adopted the Rule 10b5-1 trading plan. |
| 11/18/2025 | Date of transaction where 75,633 shares of common stock were sold. |
| 11/19/2025 | Date of transaction where 49,956 shares of common stock were sold and the filing was signed. |
Keywords
Tyra Biosciences, TYRA, Insider Sale, Form 4, Daniel Bensen, 10b5-1 Plan, Common Stock, Officer Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.